IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?
This article was originally published in Start Up
Executive Summary
Valuation Watch: an analysis of pre-money step ups for the 2003-04 biotech IPO window demonstrates that public investors are favoring companies in some therapeutic areas over companies in other areas. CNS and jump-start technologies, for example, are doing well.
You may also be interested in...
Can a Hippo Save the IPO Market for Life Sciences?
A group of private enterprises are working to revive the moribund IPO market for venture-backed start-ups.
Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology
The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology
The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.